Trial Profile
Evaluate the efficacy of an induction regimen with antithymocyte-globulin and basiliximab in patients undergoing kidney transplantation: single center experience
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 19 Aug 2015
Price :
$35
*
At a glance
- Drugs Antithymocyte globulin (Primary) ; Basiliximab (Primary)
- Indications Renal transplant rejection
- Focus Therapeutic Use
- 19 Aug 2015 New trial record